-$0.56 EPS Expected for Kalvista Pharmaceuticals Inc (KALV) This Quarter

Wall Street brokerages forecast that Kalvista Pharmaceuticals Inc (NASDAQ:KALV) will report earnings per share of ($0.56) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Kalvista Pharmaceuticals’ earnings. The highest EPS estimate is ($0.49) and the lowest is ($0.62). Kalvista Pharmaceuticals posted earnings per share of ($0.49) in the same quarter last year, which would indicate a negative year over year growth rate of 14.3%. The company is scheduled to report its next quarterly earnings report on Friday, March 15th.

According to Zacks, analysts expect that Kalvista Pharmaceuticals will report full-year earnings of ($1.79) per share for the current financial year, with EPS estimates ranging from ($2.11) to ($1.66). For the next financial year, analysts forecast that the business will post earnings of ($3.02) per share, with EPS estimates ranging from ($4.21) to ($1.83). Zacks’ EPS calculations are an average based on a survey of research firms that follow Kalvista Pharmaceuticals.

Kalvista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Friday, December 14th. The specialty pharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.46) by $0.24. Kalvista Pharmaceuticals had a negative return on equity of 29.46% and a negative net margin of 84.47%. The business had revenue of $5.59 million during the quarter, compared to analyst estimates of $3.70 million.

Several research firms have commented on KALV. Cantor Fitzgerald reissued a “buy” rating and set a $32.00 price objective on shares of Kalvista Pharmaceuticals in a report on Friday, December 14th. BidaskClub downgraded shares of Kalvista Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 7th. ValuEngine raised shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Zacks Investment Research raised shares of Kalvista Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, November 20th. Finally, TheStreet raised shares of Kalvista Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Thursday, December 20th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $26.00.

KALV stock traded up $0.75 during trading on Thursday, reaching $20.75. The company’s stock had a trading volume of 1,703 shares, compared to its average volume of 50,283. Kalvista Pharmaceuticals has a 1 year low of $7.73 and a 1 year high of $25.57. The firm has a market capitalization of $348.82 million, a PE ratio of -13.49 and a beta of 2.38.

In related news, major shareholder Life Sciences Fund Iv (Gp) Sv sold 2,136 shares of the stock in a transaction dated Wednesday, December 19th. The shares were sold at an average price of $20.02, for a total value of $42,762.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Svlsf Iv, Llc sold 3,734 shares of the stock in a transaction dated Friday, December 28th. The shares were sold at an average price of $20.03, for a total transaction of $74,792.02. The disclosure for this sale can be found here. Insiders have sold a total of 57,142 shares of company stock valued at $1,113,851 in the last three months. Insiders own 38.40% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Flinton Capital Management LLC bought a new stake in Kalvista Pharmaceuticals in the fourth quarter worth about $26,000. Ramsey Quantitative Systems bought a new stake in Kalvista Pharmaceuticals in the fourth quarter worth about $35,000. Bank of Montreal Can bought a new stake in Kalvista Pharmaceuticals in the fourth quarter worth about $90,000. BlackRock Inc. lifted its stake in Kalvista Pharmaceuticals by 203.8% in the second quarter. BlackRock Inc. now owns 16,205 shares of the specialty pharmaceutical company’s stock worth $132,000 after purchasing an additional 10,871 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in Kalvista Pharmaceuticals in the third quarter worth about $216,000. 74.12% of the stock is owned by hedge funds and other institutional investors.

Kalvista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Featured Article: What is a blue-chip stock?

Get a free copy of the Zacks research report on Kalvista Pharmaceuticals (KALV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit